---
layout: minimal-medicine
nav_exclude: true
title: Pertuzumab
---

# Pertuzumab

**Generic Name:** Pertuzumab-txab

**Usage:**

Pertuzumab-txab is a targeted therapy used in the treatment of certain types of breast cancer.  Specifically, it's used in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer who haven't received prior anti-HER2 therapy. It's also used in combination with trastuzumab and adjuvant chemotherapy (typically docetaxel) in patients with HER2-positive early-stage breast cancer after surgery.  The specific regimen will be determined by a doctor based on individual patient needs and the stage of their cancer.  It is *not* a standalone treatment.

**Side Effects:**

Like all medications, pertuzumab-txab can cause side effects, ranging in severity from mild to severe. Some common side effects include:

* **Infusion-related reactions:** These can range from mild (flushing, chills) to severe (hypotension, shortness of breath).  Close monitoring during infusions is essential.
* **Cardiotoxicity:**  Pertuzumab can affect the heart, leading to decreased ejection fraction (the heart's ability to pump blood).  Regular heart function monitoring is crucial.
* **Diarrhea:** Can be significant and require management.
* **Nausea and vomiting:** Common side effects often manageable with antiemetic medications.
* **Fatigue:** A common side effect of cancer treatments.
* **Headache:** Often mild and manageable.
* **Rash:** Can range from mild to severe.
* **Low blood counts (neutropenia, thrombocytopenia, anemia):**  Increases risk of infection and bleeding.
* **Pneumonitis (lung inflammation):** A serious but rare side effect.


This is not an exhaustive list, and the severity and frequency of side effects can vary greatly among individuals.  It is crucial to report any concerning side effects to your healthcare provider immediately.

**How it Works:**

Pertuzumab is a monoclonal antibody that targets HER2 (human epidermal growth factor receptor 2), a protein found on the surface of some breast cancer cells.  It works by binding to a different site on the HER2 receptor than trastuzumab (another common HER2-targeted therapy), thus preventing the HER2 receptors from dimerizing (pairing up) and sending signals that stimulate cancer cell growth and division. By blocking this signaling pathway, pertuzumab helps to slow or stop the growth of cancer cells.  The combined effect of pertuzumab and trastuzumab is synergistic and more effective than either drug alone.

**FAQs:**

* **Is pertuzumab-txab the same as Herceptin?** No. Herceptin is the brand name for trastuzumab, a different but similarly acting HER2-targeted therapy.  Pertuzumab and trastuzumab are often used together.
* **How is pertuzumab-txab administered?** It's given intravenously (IV) by infusion over a period of time.
* **How long is the treatment course?** The duration of treatment depends on the individual's response to therapy and the stage of their cancer. It is determined by the oncologist.
* **What are the monitoring requirements during treatment?** Regular monitoring of heart function, blood counts, and

**Note:** This information is AI-generated or crowd-sourced and may not be accurate. Please consult a medical professional for verified advice.